Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Climb Bio, Inc. (CLYM)

Climb Bio Q3 net loss widens to $14.6 million; cash totals $227.6 million

Mixed Impact 3 of 5 earnings Written later

Climb Bio reported a third-quarter 2026 net loss of $14.6 million, up from $12.9 million a year earlier, as R&D spending rose to $11.0 million. Net loss per share narrowed to $0.18 from $0.19, and the company said its $227.6 million cash position funds operations into the second half of 2028. The filing also updated clinical programs for budoprutug and CLYM116, including dosing in a Phase 2 trial and additional data expected in 2027.

Key points

  • Q3 2026 net loss was $14.6 million versus $12.9 million in Q3 2025; net loss per share was $0.18 versus $0.19.
  • R&D expenses rose to $11.0 million from $9.1 million; G&A was flat at $5.8 million.
  • Cash, cash equivalents and marketable securities were $227.6 million as of September 30, 2026, with runway expected into the second half of 2028.
  • CLYM116 NAVIGATE-2 Phase 2 trial in IgA nephropathy began dosing, with initial data expected in the first half of 2027.

The filing

CompanyClimb Bio, Inc. (CLYM)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:09 AM ET
Accession number0001193125-26-448556

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.